Kenvue (NYSE:KVUE) Releases FY 2025 Earnings Guidance

Kenvue (NYSE:KVUE) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.440-1.469 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of $15.3 billion-$15.6 billion, compared to the consensus revenue estimate of $15.9 billion.

Kenvue Stock Performance

Shares of KVUE opened at $20.74 on Thursday. The company’s 50 day simple moving average is $21.77 and its 200-day simple moving average is $21.96. The firm has a market cap of $39.76 billion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. As a group, equities analysts predict that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.95%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analyst Ratings Changes

Several research firms have issued reports on KVUE. Bank of America increased their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. UBS Group decreased their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. Finally, Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.